...
首页> 外文期刊>Bone marrow transplantation >Impact of critical care outreach on hematopoietic stem cell transplant recipients: a cohort study.
【24h】

Impact of critical care outreach on hematopoietic stem cell transplant recipients: a cohort study.

机译:重症监护对造血干细胞移植受者的影响:一项队列研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Serious morbidity and mortality can occur after hematopoietic SCT (HSCT). Critical care outreach (CCO) can provide timely access to intensive care for hospitalized patients in need of urgent stabilization but has not been examined in HSCT. Rapid Assessment of Critical Events (RACE) team was introduced at our centre January 1, 2005. A retrospective cohort study was performed. Patients undergoing HSCT between January 1, 2000 and December 31, 2004 (n=520) formed the 'before' cohort and patients transplanted between January 1, 2005 and December 31, 2007 (n=294) formed the 'after' cohort. Non-relapse mortality at day 100 after transplant was not different in the two cohorts (26 (8.8%) post-RACE vs 53 (10.2%) pre-RACE, P=0.62). The number of failed organs at time of transfer to intensive care unit (ICU) was reduced in the post-RACE cohort (1.9 +/- 0.8 vs 2.3 +/- 1.0, P=0.04) and the incidence of cardiovascular failure was lower (23.8 vs 43.8%, P=0.04). Other secondary outcomes were not different, including the frequency of ICU admission. RACE may contribute to earlier stabilization during critical illness in patients undergoing HSCT but does not reduce non-relapse mortality. CCO should be studied prospectively in patients undergoing HSCT to better evaluate its role.
机译:造血SCT(HSCT)后可能发生严重的发病率和死亡率。重症监护扩展(CCO)可以为需要紧急稳定的住院患者提供及时的重症监护服务,但尚未在HSCT中进行检查。我们于2005年1月1日在我们的中心引入了紧急事件快速评估(RACE)团队。该研究进行了回顾性队列研究。在2000年1月1日至2004年12月31日之间进行HSCT的患者(n = 520)构成了“之前”队列,在2005年1月1日至2007年12月31日之间进行了HSCT的患者(n = 294)构成了“之后”队列。两组患者在移植后第100天的非复发死亡率无差异(RACE后为26(8.8%),RACE前为53(10.2%),P = 0.62)。在RACE后的队列中,转移到重症监护病房(ICU)时衰竭器官的数量减少了(1.9 +/- 0.8对2.3 +/- 1.0,P = 0.04),心血管衰竭的发生率更低( 23.8 vs 43.8%,P = 0.04)。其他次要结局没有不同,包括ICU入院的频率。在进行HSCT的患者中,RACE可能有助于在危重疾病期间的早期稳定,但不会降低非复发死亡率。应该对接受HSCT的患者进行前瞻性研究,以更好地评估其作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号